On March 29, 2020, AbCellera Biologics, Inc., a biopharmaceutical company based in New York City, announced that it has entered into a multi-year licensing agreement to develop a new antibody to treat cancer.  According to the company's press release announcing the agreement, AbCellera's technology enabled it to identify and develop antibodies that could be used to treat cancer.  The company also announced that it had acquired a second antibody, Bamlanivimab, which is the first antibody to treat cancer.  According to the press release, Bamlanivimab is the most potent antibody ever discovered, and it has been used to treat more than 400,000 patients since 2018.  The company also announced that it has acquired a second antibody, called tramlanivimab, which is the most potent antibody currently available.  The company also announced that it has entered into an agreement to acquire tramlanivimab, the first antibody to treat cancer.  The deal is subject to approval by the U.S. Food and Drug Administration (FDA) in 2020.  The company is continuing to invest and grow its business.  The company also announced that it has agreed to pay $2.6 million in cash and $1.8 million in sales and marketing expenses.  The settlement is subject to court approval.  The SEC's continuing investigation is being conducted by Tiago Fauth, Cynthia Willey, and Puneet Souda of the Boston Regional Office.  The SEC appreciates the assistance of the U.S. Department of Health and Human Services, the Federal Bureau of Investigation, and the U.S. Department of Justice.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.govÂ Investor.govÂ to quickly identify and spot suspicious patterns.